CAMP
NASDAQCAMP4 Therapeutics Corporation
IPO2024
Price$3.19-0.21 (-6.05%)
01:30 PM07:45 PM
News · 26 weeks52-33%
2026-04-192026-10-11
Mix3090d
- Insider11(37%)
- Other8(27%)
- SEC Filings8(27%)
- Analyst2(7%)
- Offering1(3%)
Latest news
25 items- ANALYSTNeedham initiated coverage on CAMP4 Therapeutics with a new price targetNeedham initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $8.00
- PRCAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceWATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan’s 10th Annual Healthcare Conference on October 20, 2026. Details below: Chardan’s 10th Annual Healthcare Conference TitleRNA Medicines: Transcriptome EngineeringFormatPanelDate and TimeOctober 20, 2026 | 9:15-9:45 a.m. EDTLocationNew York, NYWebcast linkClick Here The eve
- ANALYSTOppenheimer initiated coverage on CAMP4 Therapeutics with a new price targetOppenheimer initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $15.00
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related DisorderAuthorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Company anticipates initiation of the clinical trial in 4Q 2026 WATERTOWN, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the company has received authorization from the United
- PRCAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadership team and participation from patient advocates and a leading KOL. To register, click here. Live webcasts can be accessed on the investor relations page of CAMP4’s website at https://investors.camp
- INSIDERChief Financial Officer Gold Kelly bought $39,600 worth of shares (10,000 units at $3.96) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- PRCAMP4 to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference Format: 1x1 meetingsDate and Time:September 8, 2026Location:Boston Cantor Global Healthcare ConferenceFormat:Fireside chat and 1x1 meetingsDate and Time:September 9, 2026, 1:00 p.m. ETLoca
- INSIDERDirector Schwab Andrew J. sold $1,616,000 worth of shares (400,000 units at $4.04) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERDirector Schwab Andrew J. sold $45 worth of shares (10 units at $4.50) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERDirector Schwab Andrew J. sold $879,719 worth of shares (191,865 units at $4.59) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERChief Scientific Officer Tardiff Daniel sold $8,273 worth of shares (1,738 units at $4.76), closing all direct ownership in the company (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by CAMP4 Therapeutics CorporationSCHEDULE 13D/A - Camp4 Therapeutics Corp (0001736730) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CAMP4 Therapeutics CorporationSCHEDULE 13G/A - Camp4 Therapeutics Corp (0001736730) (Subject)
- SECSEC Form 10-Q filed by CAMP4 Therapeutics Corporation10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECCAMP4 Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Camp4 Therapeutics Corp (0001736730) (Filer)
- PRCAMP4 Reports Second Quarter 2026 Financial Results and Corporate HighlightsSecured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year. Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028. WATERTOWN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat
- SECSEC Form EFFECT filed by CAMP4 Therapeutics CorporationEFFECT - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form 424B3 filed by CAMP4 Therapeutics Corporation424B3 - Camp4 Therapeutics Corp (0001736730) (Filer)
- SECSEC Form S-3 filed by CAMP4 Therapeutics CorporationS-3 - Camp4 Therapeutics Corp (0001736730) (Filer)
- INSIDERSEC Form 4 filed by Large owner 5am Partners Vi, Llc4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERSEC Form 4 filed by Director Schwab Andrew J.4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERDirector Young Richard A bought $27,024 worth of shares (16,378 units at $1.65), increasing direct ownership by 10% to 186,388 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERChief Medical Officer Maricich Yuri bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 108% to 12,611 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- INSIDERChief Financial Officer Gold Kelly bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 10% to 74,428 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
CAMP FAQ
5 questionsWhat does CAMP4 Therapeutics Corporation do?
CalAmp Corp. provides in telematics systems, and software and subscription services in the United States, Europe, the Middle East, Africa, South America, Asia and Pacific Rim, and internationally. The company offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things market, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from...Where does CAMP stock trade?
CAMP4 Therapeutics Corporation (CAMP) is listed on NASDAQ.When did CAMP4 Therapeutics Corporation go public?
CAMP4 Therapeutics Corporation (CAMP) completed its IPO in 2024.What are analysts saying about CAMP?
CAMP4 Therapeutics Corporation has had 8 recent analyst actions on file. The most recent action was from Needham: Buy with a $800.00 price target on 2026-10-15. Recent price targets range from $650.00 to $1500.00.How can I track CAMP on Quantisnow?
Quantisnow aggregates CAMP4 Therapeutics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAMP to receive live email and push alerts on every new disclosure.